This patent adds to the intellectual property surrounding Aveo’s proprietary and cancer biology platform.
Tuan Ha-Ngoc, president and CEO of Aveo, said: “We are very pleased to receive this patent recognizing Aveo’s mammalian second site suppressor screen (MaSS) screen technology, the cornerstone of our unique biology platform, and our innovative work in antibody and small molecule target identification for cancer.”